Explore more topics
SEC Form 13F

Atle Fund Management AB 13F Holdings

Inspect Atle Fund Management AB's 2026-06-30 SEC 13F positions, public filing date, amendments and original receipt.

As of 2026-07-25T03:59:59.999Z

Report period
2026-06-30
Publicly available
2026-07-25
Reported value
$371,704,828
Positions
39
Jump to a section

Read one actual disclosure before using it

Scroll sideways to compare all columns. Select a heading to sort.

ELI LILLY & COLLYCOM$35,768,20229,821SHNone

First displayed source row from Disclosed positions. The full bounded history and coverage notes remain below.

The displayed observation date is 2026-06-30 and its public availability date is 2026-07-25. Subtracting those calendar dates gives 25 days of disclosure lag. Historical public research can use the record from the availability date, rather than backdating knowledge to the observation date. The calendar-day difference does not assert an intraday publication time.

Read the amount together with its Unit and Option columns. A reported put or call position is not an option premium paid, and a quarterly holding is not a purchase made on its public filing date. Check every accession in the effective amendment lineage below: a retained holding can originate in an earlier filing rather than the latest linked amendment.

Open the linked original receipts to verify the row, then inspect a second record before drawing a pattern. This public filing observation supplies source evidence, not a completed copy-trading return.

Disclosed positions

Inspect all 39 displayed rows: Disclosed positions

Scroll sideways to compare all columns. Select a heading to sort.

ELI LILLY & COLLYCOM$35,768,20229,821SHNone
MERCK & CO. INCMRKCOM$24,332,374189,357SHNone
JOHNSON & JOHNSONJNJCOM$21,695,38785,425SHNone
ABBVIE INCABBVCOM$16,186,74364,325SHNone
CVS HEALTH CORPCVSCOM$15,114,251146,102SHNone
THERMO FISHER SCIENTIFIC CORPTMOCOM$13,967,38827,859SHNone
REVOLUTION MEDICINES INCRVMDCOM$13,685,86073,077SHNone
BIOGEN INCBIIBCOM$13,564,46262,781SHNone
NEUROCRINE BIOSCIENCES INCNBIXCOM$12,285,86472,898SHNone
MIRUM PHARMACEUTICALS INCMIRMCOM$11,801,475100,807SHNone
ALKERMES PLCALKSSHS$11,177,372213,329SHNone
IONIS PHARMACEUTICALS INCIONSCOM$10,873,116137,131SHNone
BEONE MEDICINES LTD-ADRONCSPONSORED ADS$10,025,24435,180SHNone
INTUITIVE SURGICAL INCISRGCOM NEW$9,805,19824,656SHNone
STRYKER CORPORATIONSYKCOM$9,534,29930,283SHNone
VERTEX PHARMACEUTICALS INCVRTXCOM$9,502,94119,131SHNone
EDWARDS LIFESCIENCES CORPEWCOM$9,338,185103,230SHNone
BRIDGEBIO PHARMA INCBBIOCOM$9,288,177124,707SHNone
KRYSTAL BIOTECH, INCKRYSCOM$8,927,14124,019SHNone
CENCORA INCCORCOM$8,808,03531,126SHNone
NEWAMSTERDAM PHARMA CO NVNAMSORDINARY SHARES$8,433,458248,848SHNone
ABIVAX SAABVXSPONSORED ADS$7,751,73458,170SHNone
INCYTE CORPINCYCOM$6,456,19256,953SHNone
IRHYTHM TECHNOLOGIES INCIRTCCOM$6,435,43254,102SHNone
BOSTON SCIENTIFCBSXCOM$6,247,541146,381SHNone
INSMED INCINSMCOM PAR $.01$6,224,26258,378SHNone
TANGO THERAPEUTICS INCTNGXCOM$6,206,891198,557SHNone
GILEAD SCIENCES INCGILDCOM$5,829,58046,142SHNone
CARDINAL HEALTH INCCAHCOM$5,613,54223,630SHNone
ORUKA THERAPEUTIORKACOM$5,223,50054,886SHNone
SPYRE THERAPEUTICS INCSYRECOM NEW$5,063,12357,030SHNone
DEXCOM INCDXCMCOM NEW$4,838,82871,846SHNone
BICARA THERAPEUTICS INCBCAXCOM$4,324,556145,657SHNone
IDEAYA BIOSCIENCES INCIDYACOM$3,521,19594,478SHNone
CELCUITY INCCELCCOM$3,485,20633,313SHNone
DISC MEDICINE INCIRONCOM$3,194,90143,682SHNone
PYXIS ONCOLOGY INCPYXSCOMMON STOCK$2,909,041966,459SHNone
COMPASS THERAPEUTICS INCCMPXCOM$2,296,4181,048,593SHNone
JADE BIOSCIENCESJBIOCOM NEW$1,967,71488,556SHNone

Largest 50 positions by reported value; the filing may contain more positions.

How amendments affect these holdings

This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.

The displayed holdings combine the effective filing versions listed here. The latest receipt linked below identifies the current projection version; it is not proof that every retained holding originated in that latest amendment. Inspect all effective accessions when verifying a position's source.

A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.

Effective SEC accessionRole in this view
0001381843-26-000005Latest effective version

Quarter end and public filing date

Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.